DrugPatentWatch Database Preview
Insulin aspart - Biologic Drug Details
Email this page to a colleague
Summary for insulin aspart
| Tradenames: | 2 |
| Patents: | 115 |
| Applicants: | 1 |
| BLAs: | 4 |
| Suppliers: see list | 3 |
| Recent Clinical Trials: | See clinical trials for insulin aspart |
| Drug Prices: | Drug price information for insulin aspart |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for insulin aspart |
Recent Clinical Trials for insulin aspart
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Medanta, The Medicity, India | N/A |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| University of Ljubljana, Faculty of Medicine | Phase 4 |
Recent Litigation for insulin aspart
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| NOVO NORDISK INC. v. SANDOZ INC. | 2020-06-04 |
| Novo Nordisk Inc. v. Sandoz Inc. | 2020-06-03 |
| Novo Nordisk Inc. v. Mylan Institutional LLC | 2019-08-20 |
Pharmacology for insulin aspart
| Established Pharmacologic Class | Insulin Analog |
| Chemical Structure | Insulin |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for insulin aspart Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for insulin aspart Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | ⤷ Try it Free | 2014-04-08 | Company disclosures |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | ⤷ Try it Free | 2014-05-06 | Company disclosures |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | ⤷ Try it Free | 2014-12-02 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for insulin aspart Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | ⤷ Try it Free | 2033-03-11 | Patent claims search |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | ⤷ Try it Free | 2033-03-14 | Patent claims search |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | ⤷ Try it Free | 2029-05-13 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for insulin aspart
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 0921812 | ⤷ Try it Free |
| Japan | 4837874 | ⤷ Try it Free |
| Norway | 863474 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for insulin aspart
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| CA 2005 00047 | Denmark | ⤷ Try it Free | PRODUCT NAME: INSULIN ASPART, PROTAMINKRYSTALLISERET |
| C990042 | Netherlands | ⤷ Try it Free | PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907 |
| 40/2005 | Austria | ⤷ Try it Free | PRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
